Recentin
From Kidney Cancer Resource
Contents |
Overview
Recentin is the marketed name of AZD-2171 manufactured by AstraZeneca
AstraZeneca Announces Recentin(R) As Global Trademark For Novel Cancer Treatment, AZD2171
AstraZeneca today (10-Jan-2007) announced RECENTIN™ as the global trademark for AZD-2171, its oral, highly potent and selective vascular endothelial growth factor (VEGF) signalling inhibitor. AZD-2171 is currently in Phase II/III development for advanced non-small cell lung cancer (NSCLC) and advanced colorectal cancer (CRC) - as well as a wide-ranging signal search programme in other Tumours.
Ian Triggs, Global Brand Strategy Director for AZD-2171 commented:
"The announcement of a brand name represents a key milestone in the development of AZD-2171"
Dr Nick Botwood, Global Medical Director for AZD-2171, added:
"Pre-clinical data shows this compound is a potent suppressor of angiogenesis - an established approach in anti-cancer treatment. More importantly, early clinical trial data has also shown encouraging anti-tumour activity with AZD-2171 and a side effect profile that appears to be predictable and manageable. The ongoing trial programme will be important to establish how AZD-2171 may add to the treatment options currently available to patients."
VEGF is a key driver of angiogenesis - the formation of new blood vessels. By inhibiting VEGF receptors, AZD-2171 hinders angiogenesis, thus preventing the blood supply that tumours need to grow and spread. There are three VEGF receptors involved in Tumour angiogenesis, (VEGFR-1, VEGFR-2, VEGFR-3).
AZD-2171 inhibits all three,1 in particular VEGFR-2, the predominant receptor through which VEGF exerts its effect on angiogenesis.
RECENTIN™ is a trademark of the AstraZeneca group of Companies.
Ongoing clinical trials with AZD-2171
The anti-Tumour efficacy of AZD-2171 is being evaluated in an extensive ongoing clinical development programme including studies in lung and colorectal cancer.
Lung cancer
Lung cancer remains the biggest cause of cancer death worldwide. Over 1.35 million new cases of lung cancer are diagnosed every year and nearly 1.2 million people die as a result of this disease - more than breast, colon and prostate cancer combined.2 A Phase II/III study, BR-24, being coordinated by the National Cancer Institute of Canada (NCIC), is comparing the efficacy of AZD-2171 plus 'doublet' Chemotherapy (paclitaxel and carboplatin) to 'doublet' Chemotherapy alone in patients with advanced NSCLC.
Colorectal cancer
Colorectal cancer is the third most commonly reported cancer worldwide, with around 945,000 new cases and 492,000 deaths annually.3 It is ranked second in terms of both incidence and mortality in more developed countries.3
The Horizon Study Programme is ongoing to evaluate AZD-2171 in patients with advanced colorectal cancer.
-- Horizon III is a Phase II/III randomised, double-blind, international multi-centre investigation of AZD-2171 in combination with FOLFOX compared to bevacizumab (Avastin(R)) in combination with FOLFOX, in patients with previously untreated metastatic colorectal cancer.
-- Horizon II, a randomised, double-blind Phase III study will compare AZD-2171 plus standard chemotherapy with standard chemotherapy alone in patients with first line advanced colorectal cancer.
-- Horizon I, a Phase II study, will evaluate AZD-2171 in combination with FOLFOX compared to bevacizumab in combination with FOLFOX, in the second-line treatment of patients with metastatic colorectal cancer.
IN DETAIL
AZD-2171 / (RECENTIN™) Ongoing studies A number of clinical trials with AZD2171 Ongoing studies are currently in progress.
More studies will be added in due course. Additional AZD-2171 Ongoing study information is available on ClinicalTrials.gov.
To view the Recentin / AZD-2171 Trials Click Here
About AZD=2171
AZD-2171 is a once-daily, orally available, highly potent and selective VEGF signalling inhibitor that inhibits all three VEGF receptors.1 The preclinical profile of AZD-2171 indicates that it has the potential to be the 'best in class' VEGF signalling inhibitor.1
AZD-2171 has shown encouraging signs of anti-Tumour activity in a clinical development programme, which has included over 700 patients to date. Phase I data indicate that AZD-2171 is generally well tolerated, with the most common dose related adverse events being diarrhoea, hoarseness, headache and hypertension.4
Click Here & see 10-Jan-2007
Articles
10-Jan-2007 - AstraZeneca Announces Recentin(R) As Global Trademark For Novel Cancer Treatment, AZD-2171
Click Here & see 10-Jan-2007
References
1 - Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jurgensmeier JM, Ogilvie DJ. Cancer Research 2005, 65: 4389-4400.
2 - Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide IARC CancerBase No. 5. version 2.0, IARCPress, Lyon, 2004.
3 - Stewart BW and Kleihues P (Eds): World Cancer Report. IARCPress. Lyon. 2003.
4 - Drevs J, Medinger M, Mross K, Zirrgiebel U, Strecker R, Unger C, Puchalski TA, Fernandes N, Roberston J, Siegert P. Proceedings from ASCO 2005, Abs 3002.
To view the original of this article Click Here
Disclaimer
Kidney Cancer Resource (KCR) is not influenced by sponsors. The information contained herein is not intended as a substitute for the advice of an appropriately qualified and licensed physician or other licensed health care provider. The information provided here is for educational and information purposes only. Early accurate Diagnosis (Dx.) saves lives. Please check with a physician if you suspect you are ill, never ignore Symptoms. To help your health care specialist make an accurate Diagnosis please keep notes of dates, times and details of your Symptoms. We are not offering medical advice nor do we consider links, individuals or articles accessed through this site to be offering medical advice.
E&OE - Errors & Omissions Excepted
As much of the information posted on this Web Site for peoples convenience is of a medical or technical nature, and may be a matter of life or death the E&OE is a Disclaimer showing that to the best of our ability information is accurate and correctly written or transcribed. Before acting on information on this site you are responsible for checking it with your relevant medical team. We can not be held responsible for any Errors & Omissions made; nor for information on links and articles provided in good faith.
